Russian courts have clarified pre-charge investigation rights in pharmaceutical sector cases. What foreign executives should know. Make an enquiry.
In advising foreign executives working in Russia's pharmaceutical industry, one observation recurs with consistency: the pre-charge investigation stage is the moment of greatest leverage — and the moment that is most frequently misunderstood. Russian criminal procedure provides for a structured pre-charge inquiry before a formal criminal case is opened, during which investigators gather information, interview persons of interest, and assess whether the threshold for criminal proceedings is met. In the pharmaceuticals sector, where the boundary between regulatory infringement and criminal liability is especially narrow, the conduct of this stage — and the judicial practice that has developed around it — carries consequences that foreign executives cannot afford to approach without experienced counsel.
The pre-charge investigation stage in Russia — known in procedural terms as the dosledstvennaya proverka, or pre-investigation check — is the period between the registration of an initial report (a complaint, an inspector's referral, or a Roszdravnadzor notification) and the formal decision either to open a criminal case or to decline to do so. Under Russian criminal procedure, this stage has a defined initial duration, subject to extension, during which investigators from the Investigative Committee, the Ministry of Internal Affairs, or, in narcotics-adjacent matters, the Federal Drug Control successor structures may take a range of procedural steps short of charging. In the pharmaceuticals sector, these steps frequently include seizure of documentation and product samples, requests for explanations from company officers, and engagement with specialised regulatory bodies for expert assessments.
For a foreign executive in a managerial position at a Russian pharmaceutical subsidiary or distribution entity, the pre-charge stage can arise from several directions: allegations of unlicensed circulation of medicinal products, violations of import or registration requirements, quality standard failures with a criminal rather than administrative characterisation, or — increasingly — matters connected to the sourcing of active pharmaceutical ingredients under post-2022 parallel import arrangements. The sector's regulatory density creates multiple potential entry points for a criminal inquiry, and the pre-charge stage is when that inquiry is at its most formative — and, in principle, most capable of being shaped by well-informed participation.
In a series of rulings handed down by Russian courts over recent years — including at the cassation and supervisory levels — the courts have progressively clarified the legal position of persons who are the subject of or connected to a pre-charge investigation. The direction of this judicial practice is significant for foreign executives in the pharmaceuticals sector and is worth examining with some care.
First, courts have consistently affirmed that the person providing explanations during a pre-charge inquiry is not a formal suspect and does not carry the procedural status entitling them to defence counsel under the provisions governing the rights of suspects. However, courts have also held that explanations provided at this stage may be relied upon in subsequent criminal proceedings — a position that creates practical tension with the absence of a formal right to counsel. The practitioner consequence is that explanations given without legal support can, and in documented practice do, form part of the evidentiary base once a criminal case is formally opened.
Second, courts have addressed the question of the duration and permissible extension of the pre-charge stage. Judicial practice has held that successive extensions must be grounded in documented investigative necessity, and that a pre-charge inquiry cannot be used as an indefinite holding pattern to avoid the procedural obligations that attach once a criminal case is formally opened. In the pharmaceuticals sector, where expert assessment of product quality or licensing status may genuinely require extended time, courts have recognised extended durations — but have also, in some instances, found procedural violations where extension requests lacked adequate grounding.
Third, and of particular relevance to foreign executives, courts have addressed the rights of persons in relation to document seizure at the pre-charge stage. The prevailing judicial approach distinguishes between voluntary submission of documents and coercive seizure, with different procedural requirements attaching to each. Where seizure at the pre-charge stage has exceeded the procedural limits — particularly in pharmaceutical company searches that proceeded without proper authorisation — courts have, in a number of matters, found the resulting evidence to be procedurally tainted, though the consequences of such a finding at trial vary and are subject to judicial discretion.
"Russian courts have, through their decisions on the pre-charge stage, created a body of practice that a well-instructed executive can navigate — but the window for protecting one's position is narrow and closes quickly once explanations are given." — Vitaliy Vetrov, Managing Partner, Vetrov & Partners
If you or a colleague in a senior role at a Russian pharmaceutical business is the subject of a pre-charge inquiry, speak to our team before providing any formal explanations — info@vetrovpartners.com |
The practical implications of this line of judicial practice divide neatly across three dimensions.
The first is timing. The pre-charge stage is time-bounded, and the investigator's ability to shape the outcome is at its greatest in the early days after an inquiry is registered. A foreign executive who understands the procedural framework — that explanations are not legally compelled at this stage, that certain document production requests may be contested, and that the formal opening of a criminal case has a specific evidential threshold — is in a materially different position from one who engages with investigators as though the process were a routine regulatory audit. The judicial practice confirming that pre-charge explanations carry evidentiary weight downstream makes early engagement with counsel not merely prudent but procedurally consequential.
The second is sector-specific legal exposure. The pharmaceuticals sector in Russia operates under a licensing and quality assurance framework administered by Roszdravnadzor, with criminal liability provisions that can be triggered by conduct that would, in other sectors, carry only administrative consequences. Courts adjudicating pharmaceutical criminal matters have shown a willingness to treat regulatory violations — particularly those involving product quality, unauthorised substitution of registered formulations, or import without proper documentation — as the factual predicate for criminal proceedings where the scale or pattern of conduct crosses the relevant threshold. A foreign executive with signing authority over procurement, quality assurance, or regulatory submissions is in the category of persons most likely to be the subject of a pre-charge inquiry in this sector.
The third is the cross-border dimension. Foreign executives working in Russia under employment agreements with Russian legal entities are subject to Russian criminal jurisdiction for conduct performed in Russia, regardless of their nationality or of their employer's corporate structure. The practical question — which courts have not addressed directly but which arises in our instructions from foreign clients — is what obligations attach to a foreign national who is contacted at the pre-charge stage while outside Russia. The conservative and well-grounded position is that the legal framework does not create a procedural obligation for a non-resident foreign national to return to Russia to provide explanations at the pre-charge stage, but this position requires careful handling: the wrong response to an investigator's communication can escalate rather than protect. For a detailed treatment of the procedural navigation at this stage, see Navigating the pre-charge investigation stage under Russian criminal procedure and, for the relevant Supreme Court guidance, Russian Supreme Court clarification on the pre-charge investigation stage.
Foreign executives who want to understand the wider Business Crime Defence practice at Vetrov & Partners — including the firm's work in matters before Russian criminal courts and the Investigative Committee — can find an overview at Business Crime Defence. A record of relevant completed instructions is at /matters/.
To discuss the specifics of your situation in confidence — info@vetrovpartners.com |
Q: What specifically changed in how Russian courts treat the pre-charge investigation stage?
A: Over a series of decisions, Russian courts have clarified two points with particular clarity: first, that explanations given at the pre-charge stage are admissible in subsequent criminal proceedings, even though the person giving them does not yet carry formal suspect status; and second, that investigative extensions at this stage must be grounded in documented necessity and cannot run indefinitely. For pharmaceutical sector matters, the practical result is that the pre-charge stage is no longer a procedurally neutral inquiry — it shapes the evidentiary record that follows.
Q: What should a foreign executive do if contacted by Russian investigators at the pre-charge stage in a pharmaceuticals matter?
A: The first and most important step is to obtain qualified Russian criminal defence counsel before providing any explanations or submitting any documents. This is not a matter of asserting guilt or innocence — it is a matter of understanding which actions at this stage are legally compelled and which are not, and of ensuring that whatever engagement occurs does not inadvertently foreclose options that remain available. The judicial practice described in this commentary confirms that the pre-charge stage is not merely preliminary: it is part of the evidentiary process.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry